Current concepts of the pathogenesis and treatment of hypertrophic cardiomyopathy

Circulation

Volumn 112, Issue 2, 2005, Pages 293-296

  Roberts, Robert ^a,c   Sigwart, Ulrich ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL   (Switzerland)

^c NONE   (Canada)

Author keywords

Ablation, alcohol; Cardiomyopathy; Death, sudden; Genetics; Hypertrophy

Indexed keywords

ANGIOTENSIN ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; PROPRANOLOL; VERAPAMIL;

ELECTROPHYSIOLOGY; GENETIC SCREENING; HEART PACING; HEMODYNAMICS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MUSCLE RESECTION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; CARDIOMYOPATHY, HYPERTROPHIC; FIBROBLASTS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTROPHY; MUTATION; PROTEINS;

EID: 22144443150     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000146788.30724.0A     Document Type: Review

References (20)

1. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348:295-303.
2. Gollob MH, Green MS, Tang AS, et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med. 2001;344:1823-1831.
3. Arad M, Benson DW, Perez-Atayde AR, et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest. 2002;109:357-362.
4. Marian AJ, Yu QT, Mann DL, et al. Expression of a mutation causing hypertrophic cardiomyopathy disrupts sarcomere assembly in adult feline cardiac myocytes. Circ Res. 1995;77:98-106.
5. Marian AJ, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2001;33:655-670.
6. Kai H, Muraishi A, Sugiu Y, et al. Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circ Res. 1998;83:594-601.
7. Derchi G, Bellone P, Chiarella F, et al. Plasma levels of atrial natriuretic peptide in hypertrophic cardiomyopathy. Am J Cardiol. 1992;70: 1502-1504.
8. Lakkis N, Nagueh S, Killip D, et al. Nonsurgical septal reduction therapy for symptomatic hypertrophic obstructive cardiomyopathy: The Baylor Experience (1996-1999). J Interv Cardiol. 2000;13:157-159.
9. Brugada R, Kelsey W, Lechin M, et al. Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy. J Investig Med. 1997;45:542-551.
10. Marian AJ, Zhao G, Seta Y, et al. Expression of a mutant (Arg92Gln) human cardiac troponin T, known to cause hypertrophic cardiomyopathy, impairs adult cardiac myocyte contractility. Circ Res. 1997;81:76-85.
11. Rust EM, Albayya FP, Metzger JM. Identification of a contractile deficit in adult cardiac myocytes expressing hypertrophic cardiomyopathy-associated mutant troponin T proteins. J Clin Invest. 1999;103: 1459-1467.
12. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J. 2003;24:1965-1991.
13. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995;346:211-214.
14. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation. 1998;98:2415-2421.
15. Nagueh SF, Ommen SR, Lakkis NM, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001;38: 1701-1706.
16. Gietzen FH, Leuner CJ, Raute-Kreinsen U, et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J. 1999;20:1342-1354.
17. Mazur W, Nagueh SF, Lakkis NM, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation. 2001;103:1492-1496.
18. Marian AJ, Roberts R. To screen or not is not the question-it is when and how to screen. Circulation. 2003;107:2171-2174.
19. Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation. 2001;103:789-791.
20. Patel R, Nagueh SF, Tsybouleva N, et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation. 2001;104:317-324.